BNT162b Vaccines Protect Rhesus Macaques from SARS-CoV-2

A safe and effective vaccine against COVID-19 is urgently needed in quantities that are sufficient to immunize large populations. Here we report the preclinical development of two vaccine candidates (BNT162b1 and BNT162b2) that contain nucleoside-modified messenger RNA that encodes immunogens derived from the spike glycoprotein (S) of SARS-CoV-2, formulated in lipid nanoparticles. BNT162b1 encodes a soluble, secreted trimerized receptor-binding domain (known as the RBD-foldon). BNT162b2 encodes the full-length transmembrane S glycoprotein, locked in its prefusion conformation by the substitution of two residues with proline (S(K986P/V987P); hereafter, S(P2) (also known as P2 S)). The flexibly tethered RBDs of the RBD-foldon bind to human ACE2 with high avidity. Approximately 20% of the S(P2) trimers are in the two-RBD 'down', one-RBD 'up' state. In mice, one intramuscular dose of either candidate vaccine elicits a dose-dependent antibody response with high virus-entry inhibition titres and strong T-helper-1 CD4 and IFNγCD8 T cell responses. Prime-boost vaccination of rhesus macaques (Macaca mulatta) with the BNT162b candidates elicits SARS-CoV-2-neutralizing geometric mean titres that are 8.2-18.2× that of a panel of SARS-CoV-2-convalescent human sera. The vaccine candidates protect macaques against challenge with SARS-CoV-2; in particular, BNT162b2 protects the lower respiratory tract against the presence of viral RNA and shows no evidence of disease enhancement. Both candidates are being evaluated in phase I trials in Germany and the USA, and BNT162b2 is being evaluated in an ongoing global phase II/III trial (NCT04380701 and NCT04368728).

Citing Articles

A highly stable lyophilized mRNA vaccine for Herpes Zoster provides potent cellular and humoral responses.

Munoz-Moreno R, Allaj V, Gadee E, Button J, Diaz F, Maddur M NPJ Vaccines. 2025; 10(1):49.

PMID: 40087280 DOI: 10.1038/s41541-025-01093-1.

SARS-CoV-2 spike peptide analysis reveals a highly conserved region that elicits potentially pathogenic autoantibodies: implications to pan-coronavirus vaccine development.

Diaz M, Mikulski Z, Leaman D, Gandarilla A, Da Silva N, Verkoczy A Front Immunol. 2025; 16:1488388.

PMID: 40070822 PMC: 11893414. DOI: 10.3389/fimmu.2025.1488388.

mRNA lipid nanoparticle formulation, characterization and evaluation.

Ma Y, VanKeulen-Miller R, Fenton O Nat Protoc. 2025; .

PMID: 40069324 DOI: 10.1038/s41596-024-01134-4.

Antibody-dependent enhancement of coronaviruses.

Tao T, Tian L, Ke J, Zhang C, Li M, Xu X Int J Biol Sci. 2025; 21(4):1686-1704.

PMID: 39990674 PMC: 11844293. DOI: 10.7150/ijbs.96112.

Functionality and translation fidelity characterization of mRNA vaccines using platform based mass spectrometry detection.

Stiving A, Roose B, Tubbs C, Haverick M, Gruber A, Rustandi R NPJ Vaccines. 2025; 10(1):38.

PMID: 39988579 PMC: 11847942. DOI: 10.1038/s41541-025-01082-4.

References

Corbett K, Flynn B, Foulds K, Francica J, Boyoglu-Barnum S, Werner A . Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. N Engl J Med. 2020; 383(16):1544-1555. PMC: 7449230. DOI: 10.1056/NEJMoa2024671. View

Rohou A, Grigorieff N . CTFFIND4: Fast and accurate defocus estimation from electron micrographs. J Struct Biol. 2015; 192(2):216-21. PMC: 6760662. DOI: 10.1016/j.jsb.2015.08.008. View

Mulligan M, Lyke K, Kitchin N, Absalon J, Gurtman A, Lockhart S . Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020; 586(7830):589-593. DOI: 10.1038/s41586-020-2639-4. View

Laczko D, Hogan M, Toulmin S, Hicks P, Lederer K, Gaudette B . A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice. Immunity. 2020; 53(4):724-732.e7. PMC: 7392193. DOI: 10.1016/j.immuni.2020.07.019. View

Graham B . Rapid COVID-19 vaccine development. Science. 2020; 368(6494):945-946. DOI: 10.1126/science.abb8923. View

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

Wrapp D, Wang N, Corbett K, Goldsmith J, Hsieh C, Abiona O . Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020; 367(6483):1260-1263. PMC: 7164637. DOI: 10.1126/science.abb2507. View

Meier S, Guthe S, Kiefhaber T, Grzesiek S . Foldon, the natural trimerization domain of T4 fibritin, dissociates into a monomeric A-state form containing a stable beta-hairpin: atomic details of trimer dissociation and local beta-hairpin stability from residual dipolar couplings. J Mol Biol. 2004; 344(4):1051-69. DOI: 10.1016/j.jmb.2004.09.079. View

Pallesen J, Wang N, Corbett K, Wrapp D, Kirchdoerfer R, Turner H . Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc Natl Acad Sci U S A. 2017; 114(35):E7348-E7357. PMC: 5584442. DOI: 10.1073/pnas.1707304114. View

10.

Berger Rentsch M, Zimmer G . A vesicular stomatitis virus replicon-based bioassay for the rapid and sensitive determination of multi-species type I interferon. PLoS One. 2011; 6(10):e25858. PMC: 3187809. DOI: 10.1371/journal.pone.0025858. View

11.

Kariko K, Muramatsu H, Welsh F, Ludwig J, Kato H, Akira S . Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther. 2008; 16(11):1833-40. PMC: 2775451. DOI: 10.1038/mt.2008.200. View

12.

Yang D, Chu H, Hou Y, Chai Y, Shuai H, Lee A . Attenuated Interferon and Proinflammatory Response in SARS-CoV-2-Infected Human Dendritic Cells Is Associated With Viral Antagonism of STAT1 Phosphorylation. J Infect Dis. 2020; 222(5):734-745. PMC: 7337793. DOI: 10.1093/infdis/jiaa356. View

13.

Singh D, Singh B, Ganatra S, Gazi M, Cole J, Thippeshappa R . Responses to acute infection with SARS-CoV-2 in the lungs of rhesus macaques, baboons and marmosets. Nat Microbiol. 2020; 6(1):73-86. PMC: 7890948. DOI: 10.1038/s41564-020-00841-4. View

14.

Zost S, Gilchuk P, Chen R, Case J, Reidy J, Trivette A . Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med. 2020; 26(9):1422-1427. PMC: 8194108. DOI: 10.1038/s41591-020-0998-x. View

15.

Yi C, Sun X, Ye J, Ding L, Liu M, Yang Z . Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies. Cell Mol Immunol. 2020; 17(6):621-630. PMC: 7227451. DOI: 10.1038/s41423-020-0458-z. View

16.

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J . A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020; 382(8):727-733. PMC: 7092803. DOI: 10.1056/NEJMoa2001017. View

17.

Corbett K, Edwards D, Leist S, Abiona O, Boyoglu-Barnum S, Gillespie R . SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. 2020; 586(7830):567-571. PMC: 7581537. DOI: 10.1038/s41586-020-2622-0. View

18.

Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz L, Vormehr M . COVID-19 vaccine BNT162b1 elicits human antibody and T1 T cell responses. Nature. 2020; 586(7830):594-599. DOI: 10.1038/s41586-020-2814-7. View

19.

Chi X, Yan R, Zhang J, Zhang G, Zhang Y, Hao M . A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science. 2020; 369(6504):650-655. PMC: 7319273. DOI: 10.1126/science.abc6952. View

20.

Orlandini von Niessen A, Poleganov M, Rechner C, Plaschke A, Kranz L, Fesser S . Improving mRNA-Based Therapeutic Gene Delivery by Expression-Augmenting 3' UTRs Identified by Cellular Library Screening. Mol Ther. 2019; 27(4):824-836. PMC: 6453560. DOI: 10.1016/j.ymthe.2018.12.011. View